Description

In order to determine the feasibility of utilizing novel rexinoids for chemotherapeutics and as potential treatments for neurological conditions, we undertook an assessment of the side effect profile of select

In order to determine the feasibility of utilizing novel rexinoids for chemotherapeutics and as potential treatments for neurological conditions, we undertook an assessment of the side effect profile of select rexinoid X receptor (RXR) analogs that we reported previously. We assessed pharmacokinetic profiles, lipid and thyroid-stimulating hormone (TSH) levels in rats, and cell culture activity of rexinoids in sterol regulatory element-binding protein (SREBP) induction and thyroid hormone inhibition assays.

Reuse Permissions
  • application/pdf

    Download count: 0

    Details

    Contributors
    Date Created
    • 2015-03-16
    Resource Type
  • Text
  • Collections this item is in
    Identifier
    • Digital object identifier: 10.1002/prp2.122
    • Identifier Type
      International standard serial number
      Identifier Value
      2052-1707
    Note

    Citation and reuse

    Cite this item

    This is a suggested citation. Consult the appropriate style guide for specific citation guidelines.

    Marshall, P. A., Jurutka, P. W., Wagner, C. E., Vaart, A. V., Kaneko, I., Chavez, P. I., . . . Macneill, M. (2015). Analysis of differential secondary effects of novel rexinoids: select rexinoid X receptor ligands demonstrate differentiated side effect profiles. Pharmacology Research & Perspectives, 3(2). doi:10.1002/prp2.122

    Machine-readable links